2022
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert A, Olszewski A, Kim S, Hess B, Gaballa S, Ayyappan S, Castillo J, Argnani L, Voorhees T, Saba R, Chowdhury S, Vargas F, Reis I, Kwon D, Alexander J, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link B, Logothetis C, Herrera A, Friedberg J, Kahl B, Luminari S, Zinzani P, Lossos I. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances 2022, 6: 2035-2044. PMID: 35196377, PMCID: PMC9006265, DOI: 10.1182/bloodadvances.2021006844.Peer-Reviewed Original ResearchConceptsProgression-free survivalEastern Cooperative Oncology GroupMALT-IPIRituximab maintenanceOverall survivalHerpes zosterAssociated with longer progression-free survivalPerformance status 0 to 1Associated with shorter progression-free survivalHeterogeneous non-Hodgkin lymphomasPresence of B symptomsLonger progression-free survivalShorter progression-free survivalExtranodal marginal zone lymphomaOccurrence of herpes zosterMarginal zone lymphomaInternational Prognosis IndexNon-Hodgkin's lymphomaAdvanced-stage diseaseCooperative Oncology GroupStandard-of-careAdverse prognosis factorsAssociated with occurrenceImpact OSUpfront regimens
2020
Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis
Alderuccio J, Beaven A, Shouse G, Epperla N, Stefanovic A, Torka P, Castillo J, Argnani L, Voorhees T, Alpert A, Chowdhury S, Reis I, Zhao W, Edwards D, Martin P, Kamdar M, Herrera A, Friedberg J, Zinzani P, Lossos I. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-137620.Peer-Reviewed Original ResearchExtranodal marginal zone lymphomaEntity's Board of DirectorsIncidence of infectious complicationsMarginal zone lymphomaNo survival differenceRituximab maintenanceOverall survivalMALT-IPIInfectious complicationsSurvival differencesBone marrowPrognostic factors associated with worse outcomesADC therapeuticsIncidence of herpes zoster infectionECOG performance status 0Cases of acute myeloid leukemiaFactors associated with worse outcomesNon-gastric locationPerformance status 0ECOG performance statusGastric extranodal marginal zone lymphomaExpert pathology reviewHerpes zoster infectionMajority of patientsLog-rank testOrbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance
Hirji S, Maeng M, Tooley A, Soderquist C, Annunziata J, Kazim M. Orbital marginal cell lymphoma and mantle cell lymphoma subclone in patient with monoclonal gammopathy of unknown significance. Orbit 2020, 40: 247-251. PMID: 32363993, DOI: 10.1080/01676830.2020.1760312.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaChronic lymphocytic leukemia/small lymphocytic lymphomaExtranodal marginal zone lymphomaMarginal cell lymphomaMarginal zone lymphomaResponse to rituximabSite of originIndolent lymphomaLymphocytic lymphomaMonoclonal gammopathyLymphomaAggressive phenotypeCell subclonesTumorSubclonesRituximabT(11;14GammopathyAuthors' knowledge,Patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply